Skip to content
Study details
Enrolling now

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)
NCT IDNCT06096857ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

240

Study length

about 1.2 years

Ages

2–100

Locations

1 site in MD

What this study is about

Researchers are testing a skin treatment containing R. mucosa and ground cardamom seeds for people with atopic dermatitis (eczema). The trial will last about 7 months, involving remote visits and questionnaires to assess the effect of this treatment on participants' skin condition.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo (sucrose)
  • 2.Take Roseomonas mucosa (RSM2015) and Cardamom seeds

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: To determine if R mucosa combined with ground cardamom seeds can improve symptoms of AD in patients aged 2 and older, 14 weeks after treatment discontinuation.

Secondary: To determine if R mucosa combined with ground cardamom seeds can improve symptoms of AD in patients aged 2 and older, during active treatment as well as 7 weeks after treatment discontinuation.

Body systems

Dermatology